Gerardo Priotto, Serena Kasparian, Wilfried Mutombo, Daniel Ngouama, Sara Ghorashian, Ute Arnold, Salah Ghabri, Elisabeth Baudin, Vincent Buard, Serge Kazadi-Kyanza, Médard Ilunga, Willy Mutangala, Gabriele Pohlig, Caecilia Schmid, Unni Karunakara, Els Torreele, Victor Kande
BACKGROUND: Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen. METHODS: A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT treatment centres in the Republic of the Congo and the Democratic Republic of the Congo...
July 4, 2009: Lancet